Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb;266(2):289-297.
doi: 10.1007/s00415-018-8936-2. Epub 2018 Jun 16.

Subthalamic deep brain stimulation and levodopa in Parkinson's disease: a meta-analysis of combined effects

Affiliations
Review

Subthalamic deep brain stimulation and levodopa in Parkinson's disease: a meta-analysis of combined effects

Joaquin A Vizcarra et al. J Neurol. 2019 Feb.

Abstract

Introduction: While subthalamic nucleus deep brain stimulation (STN-DBS) and levodopa improve motor symptoms in Parkinson disease (PD) to a similar magnitude, their combined effect remains unclear. We sought to evaluate whether STN-DBS and levodopa yield differential effects on motor outcomes, dyskinesia, and activities of daily living (ADL) when combined compared to when administered alone.

Methods: We conducted a meta-analysis of all studies reporting motor, dyskinesia, and ADL outcomes after bilateral STN-DBS in PD with presurgical Unified Parkinson's Disease Rating Scale (UPDRS-III) in Medication-OFF and Medication-ON states and postsurgical assessments in four conditions: Stimulation-ON/Medication-ON, Stimulation-ON/Medication-OFF, Stimulation-OFF/Medication-ON, and Stimulation-OFF/Medication-OFF. Dyskinesia duration (UPDRS item 32) and ADL (UPDRS-II) were compared between high and low postsurgical levodopa equivalent daily dose (LEDD) reduction. Random-effects meta-analyses using generic-inverse variance were conducted. Confidence in outcomes effect sizes was assessed.

Results: Twelve studies were included (n = 401 patients). Stimulation-ON/Medication-ON was associated with an UPDRS-III improvement of - 35.7 points [95% confidence interval, - 40.4, - 31.0] compared with Stimulation-OFF/Medication-OFF, - 11.2 points [- 14.0, - 8.4] compared with Stimulation-OFF/Medication-ON, and - 9.5 points [- 11.0, - 8.0] compared to Stimulation-ON/Medication-OFF within 5 years. The difference was maintained beyond 5 years by - 28.6 [- 32.8, - 24.4], - 8.1 [- 10.2, - 5.9], and - 8.0 [- 10.3, - 5.6], respectively. No difference was observed between Stimulation-ON/Medication-OFF and Stimulation-OFF/Medication-ON within and beyond 5 years. Dyskinesia duration and ADL outcomes were similar in high vs. low postsurgical LEDD reduction.

Conclusion: Subthalamic nucleus deep brain stimulation and levodopa independently lessened motor severity in PD to a similar magnitude, but their combined effect was greater than either treatment alone, suggesting therapeutic synergism.

Keywords: Deep brain stimulation; Levodopa; Parkinson; Subthalamic nucleus; Synergism.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Brain Res. 2002 Nov 15;955(1-2):138-52 - PubMed
    1. Brain. 2011 Jul;134(Pt 7):2074-84 - PubMed
    1. J Neurol Neurosurg Psychiatry. 2005 Dec;76(12):1640-4 - PubMed
    1. Parkinsonism Relat Disord. 2014 Apr;20(4):376-81 - PubMed
    1. Neurology. 2006 Jun 27;66(12):1811-6 - PubMed

LinkOut - more resources